CHROMAgar™ LIN-R作为高效筛查工具评估德国住院患者利奈唑胺耐药肠球菌患病率——2021至2022年多中心研究方法
该多中心研究在2021至2022年3个月试验期内,于12个研究中心使用CHROMAgar™ LIN-R平板直接筛查患者标本中的利奈唑胺耐药肠球菌(LRE),共使用13963块平板。442株推定LRE中192株经表型方法确认,161株送至德国国家参比中心后121株(75%)验证为LRE。各中心LRE患病率估计为1%(范围0.18%-3.7%)。作者结论认为CHROMAgar™ LIN-R是简单高效的LRE筛查工具,但高比例假阳性结果需要参考方法验证。
要点
- 12个研究中心3个月内使用13963块CHROMAgar™ LIN-R平板筛查LRE。
- 442株推定LRE中192株经表型确认,送至国家参比中心的161株中121株(75%)验证为LRE。
- 各中心LRE患病率估计为1%,中心间范围0.18%-3.7%。
核心结论
- CHROMAgar™ LIN-R是医院环境中简单高效的LRE筛查工具。
- 高比例假阳性结果要求用参考方法验证利奈唑胺耐药性。
研究设计与样本
- 多中心研究,2021至2022年3个月试验期内12个研究中心参与。
- 临床标本直接接种于CHROMAgar™ LIN-R平板。
- 抗菌药物敏感性试验采用VITEK2或纸片扩散法。
- 国家参比中心通过肉汤微量稀释法、cfr/optrA/poxtA多重PCR及23S rDNA突变限制性酶切试验确定利奈唑胺耐药。
主要发现
- 研究期间12个研究中心共使用13963块CHROMAgar™ LIN-R平板。
- 442株推定LRE中192株经表型方法确认,其中161株送至国家参比中心,121株(75%)验证为LRE。
- 53/81(65%)的利奈唑胺耐药屎肠球菌以23S rRNA基因突变作为唯一耐药机制。
- 39/40(98%)的利奈唑胺耐药粪肠球菌中optrA为主要耐药特征。
- 各中心LRE患病率估计为1%,中心间范围0.18%-3.7%。
临床怎么用
- CHROMAgar™ LIN-R可用于医院环境中直接 from 患者材料筛查LRE。
- 高比例假阳性结果需通过参考方法验证利奈唑胺耐药性。
局限性
- 高比例假阳性结果要求用参考方法验证利奈唑胺耐药性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In recent years, an increasing number of linezolid-resistant enterococci (LRE) was recognized at the German National Reference Centre (NRC) for Enterococci. National guidelines on infection prevention recommend screening for LRE in epidemiologically linked hospital settings without referring to a reliable and rapid diagnostic method. Since 2020, CHROMAgar™ provide a chromogenic linezolid screening agar, LIN-R, suitable to simultaneously screen for linezolid-resistant staphylococci and enterococci. OBJECTIVES: To assess the applicability of CHROMAgar™ LIN-R in clinical settings for detecting LRE directly from patient material and to infer prevalence rates of LRE amongst German hospital patients. METHODS: During the 3-month trial period, clinical samples were plated on CHROMAgar™ LIN-R. Antimicrobial susceptibility testing was performed using VITEK2 or disc diffusion. At the NRC, linezolid resistance was determined by broth microdilution, multiplex-PCR for cfr/optrA/poxtA and by a restriction-based assay for 23S rDNA mutations. RESULTS: The 12 participating study sites used 13 963 CHROMAgar™ LIN-R plates during the study period. Of 442 presumptive LRE, 192 were confirmed by phenotypic methods. Of these, 161 were received by the NRC and 121 (75%) were verified as LRE. Most of LR-E. faecium 53/81 (65%) exhibited a 23S rRNA gene mutation as the sole resistance-mediating mechanism, whereas optrA constituted the dominant resistance trait in LR-E. faecalis [39/40 (98%)]. Prevalence of LRE across sites was estimated as 1% (ranging 0.18%-3.7% between sites). CONCLUSIONS: CHROMAgar™ LIN-R represents a simple and efficient LRE screening tool in hospital settings. A high proportion of false-positive results demands validation of linezolid resistance by a reference method.
引用
- Bender JK, Baufeld E, Becker K, et al. CHROMAgar™ LIN-R as an efficient screening tool to assess the prevalence of linezolid-resistant enterococci in German hospital patients-a multicentre study approach, 2021-2022. J Antimicrob Chemother. 2023. PMID: 37473450. doi:10.1093/jac/dkad218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。